Cited by 393Gout, Hyperuricemia, Uric AcidHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Impact of Oxypurinol in Patients With Symptomatic Heart Failure

Open access

Hare, Joshua M., Mangal, Brian, Brown, Joanne, Fisher, Charles, Freudenberger, Ronald, Colucci, Wilson S., Mann, Douglas L., Liu, Peter, Givertz, Michael M., Schwarz, Richard P.·2008·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2008.01.068

Open this paper in CoChat — free account

Abstract

Objectives This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy.Background Increased XO activity may contribute to heart failure pathophysiology.Methods Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life.Results The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by approximately 2 mg/dl (p < 0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA <9.5 mg/dl exhibited a trend towards worsening. In addition, SUA reduction to oxypurinol correlated with favorable clinical response. Within the entire oxypurinol patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA compared with patients who worsened (-2.3 +/- 2.1 mg/dl vs. -1.0 +/- 1.9 mg/dl, p = 0.0006). In placebo patients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.Conclusions Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. However, post-hoc analysis suggests that benefits occur in patients with elevated SUA in a manner correlating with the degree of SUA reduction. Serum uric acid may serve as a valuable biomarker to target XO inhibition in heart failure. (Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2008.01.068

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications
Berry, C. E., & Hare, J. M. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055913 · Cited by 925
Self-citation
Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging
Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C. H., Cicoira, M., Shamim, W., Kemp, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000065637.10517.a0 · Cited by 593
High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid
Casella, G., Carr, E., Davies, J. I., Belch, J. J. F., & Struthers, A. D. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 574
Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity
Watanabe, S., Kang, D., Feng, L., Nakagawa, T., Kanellis, J., Lan, H. Y., Mazzali, M., & Johnson, R. J. (2002) · Hypertension · doi:10.1161/01.hyp.0000028589.66335.aa · Cited by 562
Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure
Landmesser, U., Spiekermann, S., Dikalov, S., Tatge, H., Wilke, R., Kohler, C., Harrison, D. G., Hornig, B., & Drexler, H. (2002) · Circulation · doi:10.1161/01.cir.0000041431.57222.af · Cited by 525
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
Self-citation
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure
Packer, M. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.25652 · Cited by 397
Electron Spin Resonance Characterization of Vascular Xanthine and NAD(P)H Oxidase Activity in Patients With Coronary Artery Disease
Spiekermann, S., Landmesser, U., Dikalov, S., Bredt, M., Gamez, G., Tatge, H., Reepschläger, N., Hornig, B., Drexler, H., & Harrison, D. G. (2003) · Circulation · doi:10.1161/01.cir.0000056762.69302.46 · Cited by 298
Angiotensin II Induces Endothelial Xanthine Oxidase Activation: Role for Endothelial Dysfunction in Patients With Coronary Disease
Landmesser, U., Spiekermann, S., Preuss, C., Sorrentino, S., Fischer, D., Manes, C., Mueller, M., & Drexler, H. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000258415.32883.bf · Cited by 210

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 101–200 of 393

‘Ryanopathy’: causes and manifestations of RyR2 dysfunction in heart failure
Belevych, A. E., Radwański, P., Carnes, C. A., & Györke, S. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt024 · Cited by 74
Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal
Neogi, T., Casella, G., Rekhraj, S., Struthers, A. D., Choi, H. K., & Terkeltaub, R. A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33369 · Cited by 73
Cardiorenal Syndrome and Heart Failure—Challenges and Opportunities
Yogasundaram, H., Chappell, M. C., Braam, B. G., & Oudit, G. Y. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.04.002 · Cited by 83
Uric acid and cardiometabolic diseases
Lee, S. J., Oh, B. K., & Sung, K. (2020) · Clinical Hypertension · doi:10.1186/s40885-020-00146-y · Cited by 80
Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases
Kuwabara, M., Fukuuchi, T., Aoki, Y., Mizuta, E., Ouchi, M., Kurajoh, M., Maruhashi, T., Tanaka, A., Morikawa, N., Nishimiya, K., et al. (2023) · Biomolecules · doi:10.3390/biom13101519 · Cited by 79
Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure
Wu, A. H., Ghali, J. K., Neuberg, G. W., O’Connor, C. M., Carson, P. E., & Levy, W. C. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.006 · Cited by 70
Review of Urate-Lowering Therapeutics: From the Past to the Future
Jenkins, C., Hwang, J. H., Kopp, J. B., Winkler, C. A., & Cho, S. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925219 · Cited by 73
Xanthine Oxidase Inhibition Prevents Atrial Fibrillation in a Canine Model of Atrial Pacing‐Induced left Ventricular Dysfunction
Sakabe, M., Fujiki, A., Sakamoto, T., Nakatani, Y., Mizumaki, K., & Inoue, H. (2012) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2012.02356.x · Cited by 69
Myeloperoxidase and Related Biomarkers are Suggestive Footprints of Endothelial Microvascular Inflammation in HFpEF Patients
Hage, C., Michaëlsson, E., Kull, B., Miliotis, T., Svedlund, S., Linde, C. M., Donal, E., Daubert, J., Gan, L., & Lund, L. H. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12700 · Cited by 69
Pathophysiology of Heart Failure
Mann, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00025-1 · Cited by 69
Self-citation
Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects
Cortese, F., Giordano, P., Scicchitano, P., Faienza, M. F., Pergola, G. D., Calculli, G., Meliota, G., & Ciccone, M. M. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2019.106565 · Cited by 67
Mitochondrially-targeted treatment strategies
Bozi, L. H. M., Campos, J. C., Zambelli, V. O., Ferreira, N. D., & Ferreira, J. C. B. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100836 · Cited by 67
Urate-Lowering Drugs and Prevention of Cardiovascular Disease
Borghi, C., & Desideri, G. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06531 · Cited by 66
Serum Uric Acid, Influence of Sacubitril–Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF
Selvaraj, S., Claggett, B. L., Pfeffer, M. A., Desai, A. S., Causland, F. R. M., McGrath, M. M., Anand, I. S., van Veldhuisen, D. J., Køber, L., Janssens, S. P., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1984 · Cited by 64
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution
Stamp, L. K., & Dalbeth, N. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.07.015 · Cited by 65
Sacubitril/Valsartan Reduces Serum Uric Acid Concentration, An Independent Predictor of Adverse Outcomes in PARADIGM-HF
Mogensen, U. M., Køber, L., Jhund, P. S., Desai, A. S., Senni, M., Kristensen, S. L., Dukát, A., Chen, C., Ramires, F. J. A., Lefkowitz, M. P., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1056 · Cited by 61
Oxidative Stress and Heart Failure in Altered Thyroid States
Mishra, P., & Samanta, L. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/741861 · Cited by 59
Targeting NOS as a therapeutic approach for heart failure
Tang, L., Wang, H., & Ziolo, M. T. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.013 · Cited by 60
Aberrant S-nitrosylation mediates calcium-triggered ventricular arrhythmia in the intact heart
Cutler, M. J., Plummer, B. N., Wan, X., Sun, Q.-A., Hess, D. T., Liu, H., Deschênes, I., ROSENBAUM, D. S., Stamler, J. S., & Laurita, K. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210565109 · Cited by 59
Redox signaling in heart failure and therapeutic implications
Weissman, D., & Maack, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.013 · Cited by 60
Mitochondria as Key Targets of Cardioprotection in Cardiac Ischemic Disease: Role of Thyroid Hormone Triiodothyronine
Forini, F., Nicolini, G., & Iervasi, G. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036312 · Cited by 57
Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia
Springer, J., Tschirner, A., Hartmann, K., Palus, S., Wirth, E. K., Busquets, S., Möller, N., von Haehling, S., Argilés, J. M. A., Köhrle, J., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27494 · Cited by 56
Hyperuricemia: a novel old disorder—relationship and potential mechanisms in heart failure
Borghi, C., Palazzuoli, A., Landolfo, M., & Cosentino, E. R. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09869-z · Cited by 57
Uric acid lowering therapy in cardiovascular diseases
Volterrani, M., Iellamo, F., Sposato, B., & Romeo, F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.088 · Cited by 53
Regulation of cardiovascular cellular processes by S-nitrosylation
Schulman, I. H., & Hare, J. M. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.04.002 · Cited by 52
Self-citation
Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the Acute HEart FAilure Database registry
Málek, F., Ošťádal, P., Pařenica, J., Jarkovský, J., Vítovec, J., Widimský, P., Linhart, A., Fedorco, M., Coufal, Z., Miklík, R., et al. (2012) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.03.011 · Cited by 53
Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition
Harzand, A., Tamariz, L. J., & Hare, J. M. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00262.x · Cited by 53
Self-citation
Uric acid in heart failure: a biomarker or therapeutic target?
Kaufman, M., & Guglin, M. E. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9322-2 · Cited by 52
Gout, Hyperuricemia, and the Risk of Cardiovascular Disease: Cause and Effect?
Shah, A., & Keenan, R. T. (2010) · Current Rheumatology Reports · doi:10.1007/s11926-010-0084-3 · Cited by 52
Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure
Palazzuoli, A., Ruocco, G. M., Pellegrini, M., Beltrami, M., Giordano, N. G., Nuti, R., & McCullough, P. A. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.039 · Cited by 52
Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure
Packer, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023538 · Cited by 53
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure
Correale, M., Paolillo, S., Mercurio, V., Limongelli, G., Barillà, F., Ruocco, G. M., Palazzuoli, A., Scrutinio, D., Lagioia, R., Lombardi, C., et al. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.008 · Cited by 54
Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure
Askevold, E. T., Gullestad, L. L., Dahl, C. P., Yndestad, A., Ueland, T., & Aukrust, P. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0185-9 · Cited by 49
The Dilated, Restrictive, and Infiltrative Cardiomyopathies
Hare, J. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00068-8 · Cited by 50
Self-citation
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease: Japanese Guideline on the Management of Asymptomatic Hyperuricemia
Hisatome, I., Li, P., Miake, J., Mahati, E., Bahrudin, U., Ninomiya, H., Taufiq, F., Mahati, E., Maharani, N., Utami, S. B., et al. (2021) · Institutional Repositories DataBase (IRDB) · Cited by 49
Hyperuricemia, A new cardiovascular risk
Kuwabara, M., Hisatome, I., Ae, R., Kosami, K., Aoki, Y., Andrés-Hernando, A., Kanbay, M., & Lanaspa, M. A. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103796 · Cited by 49
Serum Urate as a Soluble Biomarker in Chronic Gout—Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers
Stamp, L. K., Zhu, X., Dalbeth, N., Jordan, S., Edwards, N. L., & Taylor, W. J. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.09.003 · Cited by 49
The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease
Higgins, P., Dawson, J., & Walters, J. (2009) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2009/282059 · Cited by 49
Advances in pharmacotherapies for hyperuricemia
Piani, F., Agnoletti, D., & Borghi, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2197591 · Cited by 48
Immunomodulation and immunopharmacology in heart failure
Markousis‐Mavrogenis, G., Baumhove, L., Al‐Mubarak, A. A., Aboumsallem, J. P., Bömer, N., Voors, A. A., & van der Meer, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00919-6 · Cited by 51
Comorbidities in Patients with Crystal Diseases and Hyperuricemia
Sattui, S. E., Singh, J. A., & Gaffo, A. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.01.005 · Cited by 47
Prognostic value of serum uric acid in patients with acute heart failure
Huang, G., Qin, J., Deng, X., Luo, G., Yu, D., Zhang, M., Zhou, S., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014525 · Cited by 48
Evaluation of High-Sensitivity C-Reactive Protein and Uric Acid in Vericiguat-Treated Patients with Heart Failure with Reduced Ejection Fraction
Kramer, F., Voss, S., Roessig, L., Igl, B., Butler, J., Lam, C. S. P., Maggioni, A. P., Shah, S. J., & Pieske, B. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1787 · Cited by 47
Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review
Kumrić, M., Borovac, J. A., Kurir, T. T., & Božić, J. (2021) · Life · doi:10.3390/life11010053 · Cited by 49
Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement
Valsaraj, R., Singh, A. K., Gangopadhyay, K. K., Ghoshdastidar, B., Goyal, G., Batin, M., Mukherjee, D., Sengupta, U., Chatterjee, S., & Sengupta, N. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.01.007 · Cited by 46
Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?
Lubrano, V., & Balzan, S. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03656-y · Cited by 45
Biomarkers of Oxidative Stress in Heart Failure
Trachtenberg, B. H., & Hare, J. M. (2009) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.04.003 · Cited by 45
Self-citation
The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future
Mann, D. L. (2024) · Circulation Research · doi:10.1161/circresaha.123.323656 · Cited by 48
Self-citation
Beyond gout: uric acid and cardiovascular diseases
Agabiti‐Rosei, E., & Grassi, G. M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.790804 · Cited by 43
Hydralazine and Organic Nitrates Restore Impaired Excitation-Contraction Coupling by Reducing Calcium Leak Associated with Nitroso-Redox Imbalance*
Dulce, R. A., Yiğiner, Ö., González, D. R., Goss, G. M., Feng, N., Zheng, M., & Hare, J. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.412130 · Cited by 42
Self-citation
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia
Chen, C.-C., Hsu, Y., & Lee, T. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01071.2010 · Cited by 41
Xanthine oxidoreductase and its inhibitors: relevance for gout
Day, R. O., Kamel, B., Kannangara, D. R. W., Williams, K. M., & Graham, G. G. (2016) · Clinical Science · doi:10.1042/cs20160010 · Cited by 41
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Peh, Z. H., Dihoum, A., Hutton, D. L., Arthur, J. S. C., Rena, G., Khan, F., Lang, C. C., & Mordi, I. R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1125687 · Cited by 46
Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis
Tini, G., Bertero, E., Signori, A., Sormani, M. P., Maack, C., de Boer, R. A., Canepa, M., & Ameri, P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016309 · Cited by 40
Effect of Serum Insulin on the Association Between Hyperuricemia and Incident Heart Failure
Desai, R. V., Ahmed, M. I., Fonarow, G. C., Filippatos, G. S., White, M., Aban, I., Aronow, W. S., & Ahmed, A. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.023 · Cited by 40
Xanthine Oxidase Inhibitors in Heart Failure: Where Do We Go From Here?
Tamariz, L., & Hare, J. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016379 · Cited by 39
Self-citation
Heart Failure with Preserved Ejection Fraction: Pathophysiology and Emerging Therapies
From, A. M., & Borlaug, B. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00133.x · Cited by 38
The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy
Springer, J., Tschirner, A., Hartmann, K., von Haehling, S., Anker, S. D., & Doehner, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.05.063 · Cited by 38
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Yokose, C., McCormick, N., Abhishek, A., Dalbeth, N., Pascart, T., Lioté, F., Gaffo, A., FitzGerald, J. D., Terkeltaub, R. A., Sise, M. E., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01092-x · Cited by 42
Uric acid associated with acute heart failure presentation in Acute Coronary Syndrome patients
Rebora, P., Centola, M., Morici, N., Sacco, A., Occhino, G., Viola, G., Oreglia, J., Castini, D., Persampieri, S., Sabatelli, L., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.01.018 · Cited by 37
Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials
Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., & McMurray, J. J. V. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.013 · Cited by 37
Comparison of Oxidative Stress Parameters in Heart Failure Patients Depending on Ischaemic or Nonischaemic Aetiology
Romuk, E. B., Wojciechowska, C., Jacheć, W., Nowak, J. U., Niedziela, J. T., Malinowska-Borowska, J., Głogowska-Gruszka, A., Birkner, E., & Rozentryt, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7156038 · Cited by 37
Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype
Driggin, E., Helmke, S. T., Santos, J. D. L., Teruya, S. L., Guadalupe, S., Goldsmith, J., & Maurer, M. S. (2019) · Amyloid · doi:10.1080/13506129.2019.1698417 · Cited by 37
Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension
Gu, J., Fan, Y., Zhang, H., Zhang, J. J., & Wang, C. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13210 · Cited by 37
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Casella, G. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5701 · Cited by 36
Prognostic Significance of Hyperuricemia in Patients with Different Types of Renal Dysfunction and Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention
Kowalczyk, J. P., Francuz, P., Swoboda, R., Lenarczyk, R., Średniawa, B., Gołda, A., Kurek, T., Mazurek, M., Podolecki, T., Poloński, L., et al. (2010) · Nephron Clinical Practice · doi:10.1159/000314660 · Cited by 35
Allopurinol and global left myocardial function in heart failure patients
Maurice, C., & Nasr, G. M. (2010) · Journal of Cardiovascular Disease Research · doi:10.4103/0975-3583.74262 · Cited by 35
Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 36
Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients
Cicero, A. F. G., Cosentino, E. R., Kuwabara, M., Esposti, D. D., & Borghi, C. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02070-y · Cited by 34
Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications
Anders, H., Li, Q., & Steiger, S. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad006 · Cited by 37
Prognostic Significance of Serum Uric Acid in Patients Admitted to the Department of Medicine
Wasserman, A., Shnell, M., Boursi, B., & Guzner‐Gur, H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181bbb647 · Cited by 34
Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry
Ambrosio, G., Leiro, M. G. C., Lund, L. H., Coiro, S., Cardona, A., Filippatos, G. S., Ferrari, R., Piepoli, M. F., Coats, A. J. S., Anker, S. D., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.001 · Cited by 33
Hyperuricemia and the Echocardiographic Measures of Myocardial Dysfunction
Krishnan, E., Hariri, A., Dabbous, O. H., & Pandya, B. J. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00259.x · Cited by 33
Targeting Xanthine Oxidase by Natural Products as a Therapeutic Approach for Mental Disorders
Martorell, M., Lucas, X., Alarcón, P., Capó, X., Quetglas‐Llabrés, M. M., Tejada, S., & Sureda, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200621165839 · Cited by 36
The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial
Dawson, J., Quinn, T. J., Harrow, C., Lees, K. R., & Walters, M. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03497.x · Cited by 32
Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia
Nakagomi, A., Saiki, Y., Noma, S., Kohashi, K., Morisawa, T., Kosugi, M., Kusama, Y., Atarashi, H., & Shimizu, W. (2015) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2015.07.001 · Cited by 32
Xanthine Oxidase Inhibition for the Treatment of Cardiovascular Disease: An Updated Systematic Review and Meta-Analysis
Zhang, J., Dierckx, R., Mohee, K., Clark, A. L., & Cleland, J. G. F. (2016) · ESC Heart Failure · doi:10.1002/ehf2.12112 · Cited by 32
Allopurinol: novel indications in cardiovascular disease
Struthers, A. D., & Shearer, F. A. (2012) · Heart · doi:10.1136/heartjnl-2012-302249 · Cited by 32
Uric Acid is a Biomarker for Heart Failure, but Not Therapeutic Target: Result from a Comprehensive Meta-Analysis
Qin, S., Xiang, M., Gao, L., Cheng, X., & Zhang, D. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14535 · Cited by 33
Pharmacologic Strategies to Target Oxidative Stress in Heart Failure
Ahmed, Z. U., & Tang, W. H. W. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-011-0081-5 · Cited by 31
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance
Τζιόμαλος, Κ. (2009) · Frontiers in bioscience · doi:10.2741/3243 · Cited by 31
Crystallized but not soluble uric acid elicits pro-inflammatory response in short-term whole blood cultures from healthy men
Brovold, H., Lund, T., Svistounov, D., Solbu, M. D., Jenssen, T. G., Ytrehus, K., & Zykova, S. N. (2019) · Scientific Reports · doi:10.1038/s41598-019-46935-w · Cited by 32
Right ventricular phenotype, function, and failure: a journey from evolution to clinics
Taverne, Y. J. H. J., Sadeghi, A. H., Bartelds, B., Bogers, A. J. J. C., & Merkus, D. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09982-4 · Cited by 33
Role of Oxidative Stress in Disease Progression in Stage B, a Pre-cursor of Heart Failure
Bhimaraj, A., & Tang, W. H. W. (2011) · Heart Failure Clinics · doi:10.1016/j.hfc.2011.08.003 · Cited by 30
Consensus on patients with hyperuricemia and high cardiovascular risk treatment
Чазова, И. Е., Zhernakova, Y. V., Кislyak, O. A., Nedogoda, S. V., Podzolkov, V. I., Ощепкова, Е. В., Medvedeva, I. V., Mironova, O. I., & Blinova, N. V. (2019) · Systemic Hypertension · doi:10.26442/2075082x.2019.4.190686 · Cited by 31
Serum uric acid and cardiovascular disease.
Ilieșiu, A. M., Câmpeanu, A., & Dusceac, D. (2010) · Europe PMC (PubMed Central) · Cited by 30
Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF)
Yokota, T., Fukushima, A., Kinugawa, S., Okumura, T., Murohara, T., & Tsutsui, H. (2018) · International Heart Journal · doi:10.1536/ihj.17-560 · Cited by 31
Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies
Kanbay, M., Afşar, B., Siriopol, D. C., Di̇nçer, N., Erden, N., Yılmaz, O., Sag, A. A., Kuwabara, M., Cherney, D., Rossignol, P., et al. (2020) · Angiology · doi:10.1177/0003319719897509 · Cited by 29
Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction
Nogi, S., Fujita, S.-I., Okamoto, Y., Kizawa, S., Morita, H., Ito, T., Sakane, K., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00402.2015 · Cited by 28
Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases
Fiori, E., Fazio, L. D., Pidone, C., Perone, F., Tocci, G., Battistoni, A., Barbato, E., Volpe, M., Gallo, G., & the Young Group of The Italian Society of Cardiovascular Prevention (SIPREC) (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003807 · Cited by 30
Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Ameliorate Heart Failure through Reductions in Oxidative Stress: A Systematic Review and Meta-Analysis
Seth, J., Sharma, S., Leong, C. J., & Rabkin, S. W. (2024) · Antioxidants · doi:10.3390/antiox13080955 · Cited by 28
Black rice anthocyanins alleviate hyperuricemia in mice: Possible inhibitory effects on xanthine oxidase activity by cyanidin 3-O-glucoside
Feng, L.-J., Ou, W.-W., Yang, Y.-B., Qi, Y., Qi, Z., & Zhang, J. (2022) · Journal of Cereal Science · doi:10.1016/j.jcs.2021.103406 · Cited by 27
Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan
Akashi, N., Kuwabara, M., Matoba, T., Kohro, T., Oba, Y., Kabutoya, T., Imai, Y., Kario, K., Kiyosue, A., Mizuno, Y., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1062894 · Cited by 27
Oxidative Stress and Myocardial Remodeling in Chronic Mitral Regurgitation
Gladden, J. D., Ahmed, M. I., Litovsky, S. H., Darley-Usmar, V. M., McGiffin, D. C., Lloyd, S. G., Gupta, H., Dell’Italia, L. J., Schiros, C. G., & Denney, T. S. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318224ab93 · Cited by 27
Promising effects of xanthine oxidase inhibition by allopurinol on autonomic heart regulation estimated by heart rate variability (HRV) analysis in rats exposed to hypoxia and hyperoxia
Zajączkowski, S., Ziółkowski, W., Badtke, P., Zajączkowski, M. A., Flis, D. J., Figarski, A., Smolińska-Bylańska, M., & Wierzba, T. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192781 · Cited by 28
Prognostic Factors in Chronic Heart Failure
Lainščak, M., & Anker, S. D. (2009) · Herz · doi:10.1007/s00059-009-3211-z · Cited by 27
Obligatory role of neuronal nitric oxide synthase in the heart's antioxidant adaptation with exercise
Roof, S. R., Ho, H., Little, S. C., Ostler, J. E., Brundage, E. A., Periasamy, M., Villamena, F. A., Györke, S., Biesiadecki, B. J., Heymes, C., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.01.003 · Cited by 26
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Givertz, M. M., Mann, D. L., Lee, K. L., Ibarra, J. C., Velazquez, E. J., Hernandez, A. F., Mascette, A. M., & D, E. B. M. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000394 · Cited by 26
Self-citation
Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight
Furuhashi, M., Koyama, M., Matsumoto, M., Murase, T., Nakamura, T., Higashiura, Y., Tanaka, M., Moniwa, N., Ohnishi, H., Saitoh, S., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0053 · Cited by 26
Characteristic of Metabolic Status in Heart Failure and Its Impact in Outcome Perspective
Tang, H.-Y., Wang, C., Ho, H., Lin, J., Lo, C.-J., Huang, C.-Y., & Cheng, M. (2020) · Metabolites · doi:10.3390/metabo10110437 · Cited by 26

Authors: Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., Mann, D. L., Liu, P., Givertz, M. M., & Schwarz, R. P.
Affiliations: University of Miami (US)
Cardiome (Canada) (CA)
Rutgers, The State University of New Jersey (US)
Boston University (US)
Toronto General Hospital (CA)
Brigham and Women's Hospital (US)
Corresponding author: Hare, Joshua M.
ORCID: Hare, Joshua M.
Brown, Joanne
Colucci, Wilson S.
Mann, Douglas L.
Liu, Peter
Givertz, Michael M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2008-06
Volume: 51
Issue: 24
Pages: 2301-2309
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2008.01.068
OpenAlex: W1414418298
Cited by: 392
References: 25
Citations by year: 2026: 7 · 2025: 7 · 2024: 18 · 2023: 21 · 2022: 21 · 2021: 18 · 2020: 34 · 2019: 33 · 2018: 20 · 2017: 8 · 2016: 23 · 2015: 16 · 2014: 26 · 2013: 18 · 2012: 41
FWCI: 21.17
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1871 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: oxypurinol, xanthine oxidase inhibition, heart failure, systolic dysfunction, serum uric acid, hyperuricemia, biomarkers, quality of life
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Enzyme Inhibitors, Female, Health Status Indicators, Heart Failure, Humans, Male, Middle Aged, Oxypurinol, Quality of Life, Surveys and Questionnaires, Systole, Uric Acid, Xanthine Oxidase, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of Oxypurinol in Patients With Symptomatic Heart Failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks